

**The Australian Stock Exchange Limited
Companies Announcements Office
SYDNEY****16 November 2010****Chairman's AGM Speech**

Ladies and Gentlemen, welcome to the Probiomics 2010 Annual General Meeting. My name is Patrick Ford, and I am the Chairman of Probiomics Limited. Also in attendance today is my fellow director Mr Simon O'Loughlin (by phone), and the company's CFO, Mr Ashok Jairath. Our third director Mr Simon Taylor is regrettably unable to attend today's AGM, and sends his apologies.

This year the company announced a maiden net profit of \$80,144. Whilst small in real terms, the board believes this demonstrates that the cost cutting measures implemented some three years ago have been effective.

Importantly, this result was achieved in an environment in which the effect of a strong \$AUD has significantly impacted profit margins. I will request our CFO to provide an update regarding this impact during the course of this meeting.

Other highlights include:

1. The continuation of the Nestle Nutrition Infant Nutrition Agreement. The next milestone payment regarding this agreement is scheduled to be received during Q2 2011.
2. The exclusive multi level marketing agreement with USA based NuSkin continues to perform well, notwithstanding the margin compression that the company has experienced due to the strong \$AUD.
3. Registration in New Zealand of the company's proprietary probiotic strain under the ProbiaVet label for application in companion animals.

4. The continuation of the Exclusive Global Distribution Agreement with Chr.Hansen A/S of Denmark. Chr. Hansen is a global leader in the development of natural ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries, has 2,150 employees globally, a presence in 30 countries and has distributors and agents around the world.

Finally, the board wishes to advise that it will continue to pursue new opportunities with a view to creating additional shareholder value. The company's strategy will be to actively review new transactions (which may or may not be in the same sector as the company's existing business) during the course of the next financial year.

Ladies and Gentlemen thank you again for your attendance today.

Patrick Ford

Non Executive Chairman.

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary

Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au